LAB 250117 2.50P (LAB250117P2500) Stock Options, News & Quotes

0.80
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Sep 24, 2024 07:04

NEWS

$Standard BioTools (LAB.US)$
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platf...

MARKET-TEST-DUMMY

Jul 25, 2024 09:18

Insider buying

$Standard BioTools (LAB.US)$

MARKET-TEST-DUMMY

Jun 5, 2024 15:13

Keep trying

$Standard BioTools (LAB.US)$

Trytosaveabit

May 28, 2024 15:05

Hmm

$Standard BioTools (LAB.US)$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers

Trytosaveabit

May 8, 2024 15:23

Decent

$Standard BioTools (LAB.US)$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.